Treatment Selection in Pancreatic Ductal Adenocarcinoma: A Conceptual Framework for Precision Therapy

Pancreatic ductal adenocarcinoma (PDAC) remains a major therapeutic challenge, with limited improvement in outcomes and substantial heterogeneity in treatment response. Systemic chemotherapy remains a cornerstone of treatment across disease stages, yet treatment selection, particularly in metastatic PDAC (mPDAC), is still driven predominantly by clinical characteristics, performance status, prior therapy, and a limited number of molecular biomarkers. The emergence of biomarker-directed therapies, including strategies targeting oncogenic KRAS alterations, demonstrates the potential of molecularly informed treatment selection but also highlights the need to identify which therapy is most likely to benefit an individual patient at a specific clinical decision point. Recent advances in artificial intelligence (AI), multi-omics profiling, digital pathology, and prospective therapeutic trials provide an opportunity to develop comprehensive precision-treatment strategies. Existing AI approaches, including PASS-01/MULTIPL, PDACai, and CHAI, provide important foundations but remain constrained by limitations in prognostic versus predictive modeling, reliance on predominantly static or correlational representations, limited mechanistic interpretability, and incomplete integration of treatment effects and evolving tumor biology. In this narrative review, we propose a conceptual framework for individualized treatment selection in mPDAC that integrates multiscale biological and clinical data, mechanistic graph-based pathway representations, multimodal transformer models, and causal estimation of individualized treatment effects. This framework shifts AI-enabled precision oncology from static biomarker prediction toward mechanistically informed, uncertainty-aware, causally grounded treatment selection, with the potential to adapt as tumor biology, therapeutic options, and clinical evidence evolve. Although initially focused on mPDAC, the framework provides a generalizable architecture for individualized treatment selection across other biologically heterogeneous cancers.

Authors

Institutions

Publication Details

Journal
Journal of Personalized Medicine
Published
2026-11-18
DOI
https://doi.org/10.3390/jpm16110580
Primary Topic
Pancreatic and Hepatic Oncology Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Treatment Selection in Pancreatic Ductal Adenocarcinoma: A Conceptual Framework for Precision Therapy

Nelson S. Yee, Ilias Georgakopoulos‐Soares, Shucen Wan
2 links
Journal of Personalized Medicine
Pancreatic and Hepatic Oncology Research
article

Treatment Selection in Pancreatic Ductal Adenocarcinoma: A Conceptual Framework for Precision Therapy

Nelson S. Yee, Ilias Georgakopoulos‐Soares, Shucen Wan
article en

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains a major therapeutic challenge, with limited improvement in outcomes and substantial heterogeneity in treatment response. Systemic chemotherapy remains a cornerstone of treatment across disease stages, yet treatment selection, particularly in metastatic PDAC (mPDAC), is still driven predominantly by clinical characteristics, performance status, prior therapy, and a limited number of molecular biomarkers. The emergence of biomarker-directed therapies, including strategies targeting oncogenic KRAS alterations, demonstrates the potential of molecularly informed treatment selection but also highlights the need to identify which therapy is most likely to benefit an individual patient at a specific clinical decision point. Recent advances in artificial intelligence (AI), multi-omics profiling, digital pathology, and prospective therapeutic trials provide an opportunity to develop comprehensive precision-treatment strategies. Existing AI approaches, including PASS-01/MULTIPL, PDACai, and CHAI, provide important foundations but remain constrained by limitations in prognostic versus predictive modeling, reliance on predominantly static or correlational representations, limited mechanistic interpretability, and incomplete integration of treatment effects and evolving tumor biology. In this narrative review, we propose a conceptual framework for individualized treatment selection in mPDAC that integrates multiscale biological and clinical data, mechanistic graph-based pathway representations, multimodal transformer models, and causal estimation of individualized treatment effects. This framework shifts AI-enabled precision oncology from static biomarker prediction toward mechanistically informed, uncertainty-aware, causally grounded treatment selection, with the potential to adapt as tumor biology, therapeutic options, and clinical evidence evolve. Although initially focused on mPDAC, the framework provides a generalizable architecture for individualized treatment selection across other biologically heterogeneous cancers.

Journal of Personalized MedicineVol. 16(11)
Austin College (US), Pennsylvania State University (US), Penn State Cancer Institute (US), Penn State Milton S. Hershey Medical Center (US), The University of Texas at Austin (US)
Good health and well-being
Pancreatic and Hepatic Oncology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon